Get the Stockscreener App
4.07
1.50%
0.06
Olema Pharmaceuticals Inc stock is traded at $4.07, with a volume of 126.06K.
It is up +1.50% in the last 24 hours and down -13.59% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$4.01
Open:
$4
24h Volume:
126.06K
Relative Volume:
0.14
Market Cap:
$288.05M
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-1.893
EPS:
-2.15
Net Cash Flow:
$-83.73M
1W Performance:
-0.25%
1M Performance:
-13.59%
6M Performance:
-30.43%
1Y Performance:
-66.08%
1-Day Range:
$3.90
$4.1299
1-Week Range:
$3.89
$4.29
52-Week Range:
$2.86
$16.62
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
4.0685 | 288.05M | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.13 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
515.89 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.86 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
544.38 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.51 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
Deeper Dive: Understanding Olema Pharmaceuticals Inc (OLMA) Through its Various Ratios - DWinneX
Olema Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Two Sigma Investments LP Has $425,000 Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Squarepoint Ops LLC Grows Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
HC Wainwright Issues Pessimistic Outlook for OLMA Earnings - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Acquired by Wellington Management Group LLP - MarketBeat
Jane Street Group LLC Trims Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Q2 EPS Forecast for Olema Pharmaceuticals Lowered by Analyst - Defense World
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by Two Sigma Advisers LP - Defense World
ProShare Advisors LLC Purchases 3,298 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Ru - GuruFocus
Olema Oncology Expands Team with 322,000 Share Options Grant to New Biotech Talent - Stock Titan
Deutsche Bank AG Increases Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Bank of America Corp DE Has $5.05 Million Stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Millennium Management LLC Acquires 901,159 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
H.C. Wainwright Backs Olema Pharmaceuticals (OLMA) as Phase 3 Trials Advance - MSN
H.C. Wainwright maintains Buy on Olema Pharma, $28 target By Investing.com - Investing.com UK
D. E. Shaw & Co. Inc. Cuts Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Ameriprise Financial Inc. Has $2.62 Million Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Pharmaceuticals, Inc. Announces Palazestrant Dose Selection and Trial-In-Progress Poster at ASCO 2025 Annual Meeting - marketscreener.com
Olema Pharmaceuticals (OLMA) Aligns with FDA on Key Dosage for Trials | OLMA Stock News - GuruFocus
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting - GlobeNewswire
FDA Green Lights Crucial Dose for Olema's Advanced Breast Cancer Drug with 2027 Launch Target - Stock Titan
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Millennium Management LLC - Defense World
Bank of America Corp DE Increases Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Northern Trust Corp Buys 34,053 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
BNP Paribas Financial Markets Makes New $1.13 Million Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High? - MSN
Olema Oncology to Participate in Upcoming Investor Conferences - The Manila Times
Olema Oncology Advances Cancer Trials with Strong Financials - TipRanks
Olema Oncology to Participate in Upcoming Investor Conferences | - GuruFocus
Olema Oncology to Participate in Upcoming Investor Conferences | OLMA Stock News - GuruFocus
Breast Cancer Biotech Olema Sets Major Presentations at Goldman Sachs and Jefferies Healthcare Conferences - Stock Titan
Paradigm Biocapital Advisors LP Purchases 1,801,370 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Bought by MPM Bioimpact LLC - MarketBeat
Price T Rowe Associates Inc. MD Has $153,000 Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
The Goldman Sachs Group Cuts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $18.00 - Defense World
Oppenheimer Cuts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $22.00 - Defense World
Q2 EPS Estimate for Olema Pharmaceuticals Raised by Analyst - Defense World
Voya Investment Management LLC Cuts Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Driehaus Capital Management LLC Invests $1.28 Million in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS), Aquestive Therapeutics (AQST) and Olema Pharmaceuticals (OLMA) - The Globe and Mail
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth - Yahoo Finance
Olema Pharmaceuticals (OLMA) Price Target Lowered by Oppenheimer - GuruFocus
Balyasny Asset Management L.P. Increases Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals (OLMA) Price Target Lowered by Goldman Sachs | OLMA Stock News - GuruFocus
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):